- Report
- September 2024
- 100 Pages
Global
From €5242EUR$5,950USD£4,517GBP
- Report
- May 2025
- 196 Pages
Global
From €3123EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- February 2025
- 200 Pages
Global
From €3956EUR$4,490USD£3,409GBP
- Report
- July 2025
- 194 Pages
Global
From €5154EUR$5,850USD£4,441GBP
- Report
- July 2025
- 288 Pages
Global
From €5154EUR$5,850USD£4,441GBP
- Report
- June 2025
- 185 Pages
Global
From €3370EUR$3,825USD£2,904GBP
€3965EUR$4,500USD£3,416GBP
- Report
- April 2023
- 111 Pages
Global
From €4185EUR$4,750USD£3,606GBP
- Drug Pipelines
- June 2020
- 48 Pages
Global
From €1762EUR$2,000USD£1,518GBP
- Report
- December 2023
- 100 Pages
Africa
From €1762EUR$2,000USD£1,518GBP
- Report
- December 2023
- 180 Pages
Global
From €2203EUR$2,500USD£1,898GBP
- Report
- December 2023
- 80 Pages
United States
From €1322EUR$1,500USD£1,139GBP
- Report
- December 2023
- 80 Pages
South Korea
From €1322EUR$1,500USD£1,139GBP
- Report
- December 2023
- 80 Pages
Saudi Arabia
From €1322EUR$1,500USD£1,139GBP
- Report
- December 2023
- 80 Pages
Germany
From €1322EUR$1,500USD£1,139GBP
- Report
- December 2023
- 80 Pages
France
From €1322EUR$1,500USD£1,139GBP
- Report
- December 2023
- 80 Pages
China
From €1322EUR$1,500USD£1,139GBP
- Report
- December 2023
- 80 Pages
United Kingdom
From €1322EUR$1,500USD£1,139GBP
From €1322EUR$1,500USD£1,139GBP
- Report
- August 2023
- 90 Pages
Global
From €3500EUR$4,255USD£3,121GBP
- Report
- December 2022
- 44 Pages
Global
From €1762EUR$2,000USD£1,518GBP

Pyrimethamine is an antifolate drug used to treat a variety of infectious diseases, including toxoplasmosis, malaria, and isoniazid-resistant tuberculosis. It is also used to prevent and treat Pneumocystis jirovecii pneumonia in people with weakened immune systems. Pyrimethamine is available in both oral and injectable forms, and is often used in combination with other drugs.
The pyrimethamine market is driven by the increasing prevalence of infectious diseases, the growing demand for combination therapies, and the increasing availability of generic drugs. The market is also driven by the increasing number of clinical trials and the development of new formulations.
Companies in the pyrimethamine market include GlaxoSmithKline, Pfizer, Merck, Sanofi, Novartis, and Mylan. Show Less Read more